LeMaitre Vascular, Inc. — Q3 2014 Form 10-Q
Business context and period. Medical-device company focused on products for vascular surgery, including vascular patches and grafts, catheters, shunts, and valvulotomes. This unaudited filing covers the quarter and nine months ended September 30, 2014; amounts below are in millions of dollars unless noted.
Financial performance and liquidity
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Net sales | $17.50 | $15.30 | $52.42 | $46.63 |
| Gross profit / margin | $12.00 / 68.6% | $10.72 / 70.0% | $35.60 / 67.9% | $33.16 / 71.1% |
| Operating income | $1.85 | $0.78 | $3.60 | $3.35 |
| Net income | $0.93 | $0.72 | $2.00 | $2.46 |
| Diluted EPS | $0.05 | $0.05 | $0.12 | $0.16 |
| Operating cash flow | Not presented quarterly | Not presented quarterly | $2.83 | $4.03 |
- Q3 sales rose 14%; nine-month sales rose 12%. International sales grew 18% in Q3 and 20% year to date; the United States remained the largest reported country market.
- Q3 operating income improved substantially year over year, while nine-month net income and EPS declined. The nine-month tax provision increased to $1.63 million from $0.77 million.
- At September 30, cash and cash equivalents were $18.35 million, up from $14.71 million at year-end 2013. Current assets were $49.43 million and current liabilities $12.58 million. No long-term debt balance is shown; Xenotis acquisition debt assumed at closing was paid off in August.
- Cash from operations was $2.83 million; investing used $6.36 million, mainly for acquisitions; financing provided $7.45 million, principally reflecting approximately $10.5 million net proceeds from a June share offering. Inventory increased $3.67 million from year-end.
- Total assets were $83.50 million, including goodwill of $17.44 million and net intangible assets of $7.64 million. Acquisition-related current obligations were $2.89 million.
Material changes and unusual items
- Gross margin fell 1.4 percentage points in Q3 and 3.2 points year to date. Management cited unfavorable product and geographic mix and manufacturing cost increases; higher average selling prices and completion of the biologic-patch manufacturing transition partly offset the pressure. A one-time inventory valuation benefit in Q2 2013 also affected the year-to-date comparison.
- Nine-month operating expenses increased 7%, including $0.50 million of restructuring charges and $0.16 million of impairment charges. Restructuring followed workforce reductions and the transfer and closure of the Clinical Instruments facility; the impairment related to discontinuing a catheter product line.
- 2014 acquisitions included Xenotis, parent of the Omniflow II graft business, and the Applied Medical angioscope product line. The company also paid approximately $1.2 million to terminate five former Xenotis European distributor arrangements. Acquisition accounting and the Xenotis purchase-price adjustment remained subject to finalization.
- Foreign-currency translation losses of $1.38 million in Q3 contributed to a comprehensive loss of $0.44 million despite positive net income. Nine-month translation loss was $1.38 million.
Outlook, risks, and contingencies
- No formal full-year revenue or earnings guidance is provided. Management said cash resources should cover anticipated requirements for at least 12 months, while noting that future capital needs depend on sales, acquisitions, dividends, and expansion costs.
- Management anticipated approximately $0.5 million of Q4 revenue from the Omniflow II and angioscope product lines, with a negative gross-margin effect; the China sales office was expected to increase Q4 general and administrative expense. Expanded direct sales in Norway and Australia were expected to increase sales and marketing costs.
- The board approved a $0.035 per-share quarterly dividend for payment in December 2014. Dividends remain subject to quarterly board approval.
- Key disclosed risks include reliance on sole- or limited-source suppliers, acquisition integration and execution, sales-force productivity and product acceptance, product and geographic mix pressure on margins, foreign-exchange movements, and the ability to expand direct selling in new territories. Management also identified risks to realizing expected benefits from restructuring and acquisitions.
- Contractual obligations totaled $11.31 million: $8.19 million of operating leases and $3.13 million of inventory purchase commitments. The company reported no off-balance-sheet arrangements and no legal matters expected to have a material adverse effect. Unrecognized tax benefits were $0.08 million; management said recent German and French tax audits produced no material liability changes.
Investor verification priorities
- Check whether sales growth from acquired businesses and newer products is sustainable, and whether the acquisitions deliver expected returns.
- Track gross margin recovery against the disclosed mix, manufacturing-cost, and acquired-product pressures.
- Assess cash conversion and inventory buildup, including the effect of acquisition-related payments and future obligations.
- Monitor the final Xenotis purchase-price adjustment, distributor-termination payments, and remaining acquisition contingent consideration.
- Review the rising effective tax burden, foreign-currency exposure, and supplier continuity risks.
- Confirm subsequent-period results and whether the stated cash runway, dividend, and anticipated Q4 acquired-product sales were realized.